Legend Biotech Corporation Appoints Industry Veterans to Strategic Advisory Board
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the formation of a strategic advisory board...
Biogen
InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...
Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval
Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...
Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration
US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...
InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...
Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab
Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...
Biogen’s Aducanumab Administered to Chinese Patient for First Time
US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a...
Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China
The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...